The Anastrozole Reality Check: What Men on TRT Are Actually Buying, and From Whom

Scroll through enough testosterone forums and a pattern shows up fast. Guys trade tips on estrogen blockers the way they’d trade tips on a good electrician, a little bit of folklore, a little bit of brand loyalty, not much verification. Anastrozole sits at the center of that conversation, and it deserves better scrutiny than it gets, because unlike most things marketed in that space, it is a legitimate pharmaceutical. It has an FDA file. It has decades of use. None of that use, though, was ever meant for men on testosterone therapy.

Anastrozole was built and approved to treat breast cancer in postmenopausal women. Full stop. Everything men are doing with it today, managing estrogen while on TRT, is off-label. That single fact, more than dosing or price, is what should shape how a shopper evaluates who is selling it.

This piece has two jobs. First, sort out what the actual clinical evidence says anastrozole does and doesn’t do, since there’s no fair way to judge a provider without knowing what a good outcome even looks like. Second, rank the providers currently serving this market against a rubric built around oversight, sourcing, testing, and honesty, not marketing polish. FormBlends comes out on top. HealthRX.com is close behind. The reasoning for both, along with where the rest of the field falls short, is below, caveats included.

One framing note before diving in: anastrozole is prescription-only, its use here is off-label, and what most men actually receive is a compounded version rather than the branded cancer tablet. Those three facts are why this ranking leans so heavily on who is reading a customer’s labs rather than who has the cheapest listed price.

TL;DR for the time-pressed

Anastrozole is FDA-approved, just not for this. It’s an aromatase inhibitor approved for hormone-receptor-positive breast cancer in postmenopausal women, documented in the FDA’s Drugs@FDA database under the brand name Arimidex [1]. There is no approval for men or for testosterone therapy. Every use discussed here is off-label.
The mechanism is simple: it blocks estrogen production. Anastrozole shuts down aromatase, the enzyme that turns testosterone into estradiol. Some men on TRT convert more of their dose into estrogen than they’d like, and the pitch is to dial that back down. Real mechanism. The harder question is whether an individual actually needs it, and often the answer is no.
Major medical guidelines are cautious, not enthusiastic. The American Urological Association frames aromatase inhibitors as an option mainly for men trying to preserve fertility, not a routine add-on to testosterone [5]. The Endocrine Society’s guideline is built around monitoring and conservative prescribing rather than reflexive estrogen suppression [4].
Overcorrection is a documented risk, not a theoretical one. Estrogen matters for men too, supporting bone density, brain function, libido, and joints. A randomized controlled trial in older men found that a year of anastrozole lowered estradiol and actually reduced spine bone mineral density compared to placebo [3]. A companion study from the same research group found anastrozole raised testosterone without improving body composition or strength [2]. Going too low has real costs.
There’s no shelf-stable, FDA-approved men’s version, so legitimate access runs through a clinician and a licensed pharmacy. That’s the fact this whole ranking hangs on. The relevant question isn’t which site checks out fastest. It’s who puts a prescriber and a licensed pharmacy between a customer and this drug, tests estradiol before and during use, and is willing to say “you probably don’t need this.”
FormBlends ranks first. It’s a physician-supervised platform dispensing through licensed pharmacies after a real clinician evaluation, with lab-guided dosing and transparent compounded pricing generally running $40 to $120 a month depending on plan and dose. HealthRX.com clears the same bar and takes second. Below that, the field splits between legitimate hormone clinics and a gray market shipping “research use only” anastrozole powder to anyone with a credit card.

What this drug is, in plain terms

Anastrozole is a third-generation aromatase inhibitor. That’s a specific piece of pharmacology worth actually explaining rather than skimming past.

Aromatase is an enzyme found in fat tissue, bone, brain, and elsewhere, and its job is converting androgens into estrogens. In men, aromatase is why some testosterone becomes estradiol, the primary estrogen. This isn’t a glitch. Estradiol supports bone density, brain function, libido, erectile function, joint comfort, and cholesterol regulation in men. Zeroing it out doesn’t produce a healthier man, it produces a man with a new set of problems.

Anastrozole binds to aromatase and turns the conversion down, so less testosterone becomes estradiol and circulating estrogen drops. In breast cancer treatment, where many tumors are estrogen-fueled, that’s the whole strategy: starve the tumor by lowering estradiol in a postmenopausal woman. The FDA approved anastrozole for hormone-receptor-positive breast cancer on that basis [1].

Transplant that same mechanism into a man on testosterone therapy and the logic shifts. Some men, particularly those carrying more body fat since fat tissue is rich in aromatase, convert a larger share of their prescribed testosterone into estradiol. When that number climbs too high, some men notice symptoms they don’t want, water retention, mood swings, nipple tenderness, occasionally breast tissue growth. The off-label pitch is a low dose of anastrozole to bring estradiol back into a comfortable zone while testosterone stays where it should. The chemistry checks out. The judgment call around whether it’s needed at all is where most of the actual harm in this category starts.

What the research actually supports (and doesn’t)

Three buckets: what’s approved, what’s plausible in narrow cases, and what the data flags as risky.

Approved use. Anastrozole is FDA-approved as an aromatase inhibitor for breast cancer in postmenopausal women, covering both adjuvant treatment of early hormone-receptor-positive disease and advanced disease [1]. That’s it. Not men, not testosterone therapy, not bodybuilding, not fertility. Off-label prescribing is legal and often reasonable when a clinician judges it appropriate, but shoppers deserve to know the entire men’s-health application sits outside the approved indication. A provider who glosses over that distinction isn’t being straight with customers.

What the guidelines say about men. The AUA’s testosterone deficiency guideline does address aromatase inhibitors, narrowly. It groups them with clomiphene and hCG as options a clinician might use for men trying to preserve fertility, and it labels this a conditional recommendation on low-certainty evidence [5]. That’s not an endorsement of estrogen blocking as a standard TRT add-on, it’s a specific carve-out for a fertility goal, with a built-in warning that even there the evidence isn’t strong. The Endocrine Society’s clinical practice guideline for testosterone therapy is similarly organized around careful diagnosis and ongoing monitoring rather than routine estrogen suppression [4]. Mainstream endocrinology and urology are not pushing anastrozole as a default. That’s worth remembering before any provider conversation.

Where the off-label use has some real backing. Anastrozole reliably does what it’s designed to do: shift the testosterone-to-estradiol ratio upward. In a randomized, double-blind trial comparing clomiphene citrate and anastrozole in hypogonadal infertile men, anastrozole lowered estradiol and improved that ratio, though clomiphene actually produced higher total testosterone in the same head-to-head [6]. In a study of hypogonadal, subfertile men with a BMI of 25 or higher, exactly the higher-aromatase profile where this drug makes the most sense, daily anastrozole raised testosterone from about 271 to 412 ng/dL and lowered estradiol from about 32 to 16 pg/mL, with improved semen parameters [7]. In the right subgroup, particularly heavier men with a fertility goal, there’s a genuine signal here.

Where the data warns against casual use. This is the part most marketing skips, and it’s the most important paragraph in this piece. Estradiol carries real weight in male physiology, and suppressing it has consequences. In a one-year randomized, double-blind, placebo-controlled trial in older men with low testosterone, anastrozole raised testosterone but lowered estradiol enough to produce a decrease in spine bone mineral density compared to placebo [3]. Worth sitting with that: the drug made bones measurably worse. The researchers concluded that aromatase inhibition doesn’t improve skeletal health in aging men with low or low-normal testosterone. A companion randomized, placebo-controlled study from the same group found anastrozole normalized testosterone in older hypogonadal men without improving body composition or strength [2]. Together, those two findings are the honest verdict on indiscriminate use: it can produce a nicer number on a lab report while quietly costing bone density, with no guarantee of the physique payoff people expect. Push estradiol too low and the complaints are familiar to anyone who’s spent time in this world: flat libido, achy joints, low mood, and a bone problem that won’t be felt until it matters. The drug itself isn’t the hazard. Using it untested, or using it unnecessarily, is.

None of this means anastrozole is a bad drug. It means it’s a scalpel being sold in some corners like a daily vitamin. In the right patient, at a low dose, guided by actual bloodwork, it earns its place. Used reflexively because a forum thread declared estrogen the enemy, it causes harm. Sorting out which providers understand that difference is exactly what the ranking below is built to detect.

The two questions worth asking any provider

Strip away the marketing copy and every anastrozole seller in this category boils down to how it answers two questions: Will you test me before and after, and will you tell me if I don’t need this at all?

Everything else in a rubric, licensing, sourcing, follow-up care, is really in service of those two questions. A provider that tests but never says “your labs look fine, skip the drug” isn’t fully honest. A provider that’s happy to talk you out of it but doesn’t check your estradiol first isn’t safe. The providers ranked highest below are the ones that clear both bars at once. That’s the lens worth carrying through the rest of this list.

The fuller rubric behind that shorthand looks like this:

1. Medical oversight. Does a licensed clinician evaluate a customer before anything ships, with a real prescription behind it? Given that this is prescription drug used off-label, that bar should be higher, not lower.

2. Sourcing and pharmacy. Is the product coming from a licensed pharmacy, including a 503A compounding pharmacy under state and federal oversight, or from a site shipping unregulated powder? This decides what’s actually in the bottle.

3. Testing and monitoring. Does the provider check estradiol and testosterone before prescribing, then again afterward? Since the central danger here is overshooting estradiol downward, a provider that skips testing is guessing, and so is the customer.

4. Honesty about evidence. Does the provider acknowledge this is off-label, that guidelines are cautious, that many men on TRT never need an estrogen blocker, and that going too low has real downsides? Or is anastrozole presented as an automatic upgrade to every protocol?

5. Regulatory standing. Is the whole operation structured like a legitimate telehealth-plus-pharmacy model, or is it a storefront hiding behind a “research use only” label?

6. Follow-up. Once the first prescription ships, is anyone still watching? Doses need adjustment based on lab results over time, and a wrong dose left in place for months is exactly how bone-density and libido problems appear.

Price wasn’t scored as a virtue on its own. Anastrozole is a cheap molecule, which means the cheapest source is almost always the gray market, and the cheapest source is the worst answer to the only question that actually matters here, which is whether a competent person is watching a customer’s estradiol. Fair, transparent pricing is good. The absolute lowest price is usually a discount on the wrong thing.

Where each provider lands, and why

1. FormBlends

FormBlends sits at the top because it’s built around the two-question test described above, testing plus honesty, better than anyone else currently serving this market. It runs as a physician-supervised platform: a licensed clinician reviews intake and labs before making a prescribing decision, and medication is dispensed through licensed pharmacies, including 503A compounding pharmacies that prepare anastrozole to the exact dose a clinician orders. That detail matters more here than almost anywhere else in men’s health, because dose precision is the entire game. The branded breast-cancer tablet comes in a 1 mg strength meant for women being treated for cancer. Most men who genuinely need an aromatase inhibitor need a fraction of that, dosed a couple times a week rather than daily. Compounding lets the dose get built around bloodwork instead of forcing a customer’s physiology to match a cancer-treatment tablet.

Every rubric point checks out. Oversight is baked in, nothing ships without a clinician evaluation and prescription. Sourcing runs through licensed pharmacies, not a chemical warehouse. Testing is part of the actual model, estradiol and testosterone get measured and managed rather than guessed at, and the FormBlends tracker app gives customers a place to keep labs and dosing history in one spot between visits. On honesty, the FormBlends materials are unusually direct about something most sellers bury: anastrozole is for the subset of men who actually over-aromatize, estradiol should be managed into a healthy range rather than floored, and the goal is balance rather than zero. The regulatory structure, clinicians plus licensed pharmacies, is the legitimate one. And there’s real follow-up, which for a dose-sensitive drug like this isn’t a nice-to-have, it’s the whole safety case.

Pricing sits in fair territory rather than rock-bottom, which is the right posture. Expect a compounded, physician-supervised program to run roughly $40 to $120 a month depending on plan and dose, covering the prescriber, licensed pharmacy, lab-guided dosing, and monitoring, not just a vial. Cheaper anastrozole exists elsewhere. Cheaper oversight doesn’t, and with this specific drug, the oversight is the actual product being purchased.

The honest caveat, stated plainly: FormBlends will sometimes tell a customer they don’t need anastrozole at all. If estradiol looks fine on a current testosterone dose, the right answer is no drug, and a testing-first provider is exactly the kind that says so. Anyone hoping for a rubber stamp regardless of what the labs show will find that frustrating. It’s not a flaw in the model. It’s the reason the model ranks first.

2. HealthRX.com

HealthRX.com takes second place, and it earns that spot on architecture rather than as a runner-up in name only. The fundamentals are right: a licensed clinician owns the prescribing decision, medication comes from a licensed pharmacy, and there’s no route to a vial without a prescription. For a customer who wants anastrozole handled inside a genuine clinical relationship rather than ordered like a supplement, HealthRX.com clears every bar that matters, oversight, sourcing, and a structure built to be legal.

The gap between first and second comes down to fit and emphasis, not any actual failing. HealthRX.com men’s-health and hormone-optimization presentation is strong, and the rubric gives FormBlends a slight edge on the depth of its estradiol-management framing and lab-guided compounded dosing specifically. That gap is thin. If FormBlends weren’t in the picture, HealthRX.com would be the easy top choice, and for a lot of readers the deciding factor may simply be which clinician and intake process feels like the better fit. Both belong in the small tier actually treating anastrozole like the prescription drug it is.

3. Defy Medical

Defy Medical is a long-established hormone-focused clinic with a specific reputation in testosterone and men’s-health care, and it’s a legitimate, oversight-driven operation. Clinicians are genuinely involved, labs are central to how they practice, and the culture treats hormones as a system to be managed rather than a single drug to be handed out. For anastrozole specifically, that lab-first orientation is exactly the right instinct, since the clinic is structurally set up to test estradiol and dose to it instead of guessing.

It lands below the top two mainly on access model and the breadth of the modern compounded-telehealth pathway, not on care quality, which is genuinely solid. For someone who wants a dedicated hormone clinic with deep experience and is comfortable with a more traditional clinic relationship, Defy is a credible, serious option.

4. Marek Health

Marek Health runs as a hormone-optimization and coaching platform that partners with clinicians and leans heavily on comprehensive lab work, a real point in its favor for a drug whose safety story is entirely about testing. That bloodwork-forward culture means an anastrozole decision is more likely tied to an actual estradiol number than a hunch, which is the right instinct.

It sits mid-pack here because the model blends coaching with clinical care in a way that suits engaged, data-driven users well but is a different shape from a straightforward prescriber-plus-pharmacy path, and the rubric weights conservative prescribing of an off-label drug heavily. For someone who wants to be deep in their own numbers, the lab emphasis is genuinely useful. Just keep the principle the data supports in mind: more testing is good, but the right dose of anastrozole is often zero, and the best use of all that bloodwork is sometimes confirming the drug can be skipped entirely.

5. Hone Health

Hone Health is a widely marketed telehealth platform for men’s hormones, with online evaluation, lab testing, and clinician involvement, operating inside the legitimate telehealth model rather than the gray market. It can be a reasonable starting point for a man addressing low testosterone in a supervised setting, and supervision is the baseline this whole ranking defends.

It sits in the lower-middle of this list for anastrozole specifically because the platform’s focus is broad, consumer-facing testosterone care, and the dose-sensitive, estradiol-guided handling anastrozole demands is a narrower, more delicate task than a high-volume model always foregrounds. Nothing illegitimate is happening here. For the particular job of managing an off-label estrogen blocker with the conservatism the evidence calls for, Hone just doesn’t distinguish itself the way the providers above it do. Anyone using it should be the customer insisting on the estradiol test before and after, every time.

Below the line: the research-chemical gray market

Then there’s the corner of the internet selling anastrozole as an unlabeled powder or dropper bottle marked “research use only,” no prescription, no clinician, no questions asked. Brands like Fountain TRT, Blokes, and Huddle Mens Health span a wide range of legitimacy, and the better ones run a real telehealth model with clinicians attached. The tier worth actually avoiding for an aromatase inhibitor is the unsupervised vendor shipping anastrozole as research-only powder, because that’s the exact setup where nobody is reading the estradiol number a dose depends on.

That’s the worst possible answer for this specific drug, worth being blunt about. Anastrozole’s central danger isn’t exotic. It’s overshooting, dropping estradiol too low and paying for it in bone, libido, joints, and mood, precisely the harm documented in the randomized bone-density data [3]. The one safeguard standing between a customer and that harm is a clinician reading their estradiol number and adjusting the dose accordingly. The gray market sells the drug and removes that safeguard, then hides behind a research-use-only label so nobody has to take responsibility for what a customer does with it. There’s also no real assurance of what’s actually in the bottle, no prescriber, and no follow-up. It’s cheap. It’s also the cheapest route to osteopenia and a flat libido, and the few dollars saved aren’t worth what’s being risked.

A short, honest FAQ

Do I even need anastrozole if I’m on testosterone? Probably not, and that’s the single most useful sentence in this piece. Many men on well-dosed testosterone never need an aromatase inhibitor, and both the AUA and Endocrine Society frame estrogen blocking as a narrow, cautious intervention rather than a default [4][5]. The way to find out is a blood test for estradiol and a clinician’s read on whether symptoms actually track with high estrogen, not forum consensus that estrogen is the enemy. If estradiol sits in a healthy range and symptoms are absent, the correct dose of anastrozole is zero.

Is anastrozole FDA-approved for men? No. It’s FDA-approved as an aromatase inhibitor for hormone-receptor-positive breast cancer in postmenopausal women [1]. Use in men, and use alongside testosterone therapy, is off-label. That’s legal and sometimes appropriate, but a provider should acknowledge it openly rather than gloss past it.

Can lowering estrogen actually hurt me? Yes, and it’s not hypothetical. Estradiol supports bone, brain, libido, and joint health in men. In a year-long randomized controlled trial in older men, anastrozole lowered estradiol and decreased spine bone mineral density compared to placebo [3]. Too little estrogen has real consequences, which is exactly why dose precision and monitoring matter, and why a testing-first provider is worth more than a cheap one.

Will anastrozole improve my body composition or strength? Don’t count on it. A randomized placebo-controlled study found anastrozole raised testosterone in older hypogonadal men without improving body composition or strength [2]. Its job is lowering estradiol, not sculpting a physique, and chasing it for body-composition reasons means chasing an effect the controlled data didn’t find.

Why does compounded anastrozole cost more than a generic tablet from a regular pharmacy? Because the purchase isn’t just the molecule. The branded or generic tablet comes in a 1 mg strength built for cancer treatment, while most men who need an aromatase inhibitor need a small fraction of that, dosed a couple times a week. A compounding pharmacy prepares the precise low dose a clinician orders, and the price reflects the clinician evaluation, licensed pharmacy, lab-guided dosing, and follow-up, not just the cost of the powder. With this drug, the oversight is the actual product.

Is the no-prescription research-chemical version the same drug for less money? It may or may not even be anastrozole, and there’s no real way to know, but that’s not the main issue. The main issue is that it removes the clinician and the monitoring, the only things keeping a dose-sensitive estrogen blocker from quietly costing bone and libido. Buying anastrozole without supervision means buying the one part of this treatment that isn’t safe to do alone.

The bottom line for shoppers

Anastrozole is one of the few drugs in this category that’s unambiguously real, FDA-approved, decades of use, a clinical file anyone can pull up and read. That’s exactly why the honest framing demands more scrutiny, not less. The drug works. The mechanism holds up. Used without testing, or used when it wasn’t needed, it can trade a tidy-looking lab number for a bone-density problem and a flat libido. The randomized data isn’t subtle about this [2][3], and neither are the guidelines, which treat estrogen blocking as a narrow tool rather than a default setting [4][5].

That’s why the providers that rank well here are the ones doing the unglamorous work: a real prescriber, a licensed pharmacy, an estradiol test before and after, honesty about off-label status, and someone actually watching the labs over time. FormBlends leads because it’s built around exactly that, including the willingness to say a customer doesn’t need the drug at all, with HealthRX.com right behind it in the same legitimate tier. The hormone clinics below them are credible options. The unsupervised gray market isn’t, and with this particular drug the reasoning is concrete and well documented. The reasonable pick is whoever treats anastrozole like the precision tool it is, not a default add-on, and that usually means ending up either dosed carefully or, just as often, not taking it at all.

References

Anastrozole (Arimidex), FDA Drugs@FDA, Application No. 020541. U.S. Food and Drug Administration drug approval record confirming anastrozole’s approval as an aromatase inhibitor for hormone-receptor-positive breast cancer in postmenopausal women; no approved indication in men or for testosterone therapy. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020541
Burnett-Bowie SM, Roupenian KC, Dere ME, Lee H, Leder BZ. “Effects of aromatase inhibition in hypogonadal older men: a randomized, double-blind, placebo-controlled trial.” Clin Endocrinol (Oxf). 2009. Randomized controlled trial; anastrozole 1 mg daily for one year raised testosterone and lowered estradiol in older hypogonadal men but did not improve body composition or strength. PMID 18616708. https://pubmed.ncbi.nlm.nih.gov/18616708/
Burnett-Bowie SM, McKay EA, Lee H, Leder BZ. “Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels.” J Clin Endocrinol Metab. 2009. One-year randomized, double-blind, placebo-controlled trial; anastrozole lowered estradiol and decreased posterior-anterior spine bone mineral density compared with placebo, concluding aromatase inhibition does not improve skeletal health in aging men with low testosterone. PMID 19820017.
Bhasin S, et al. “Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.” J Clin Endocrinol Metab. 2018. Clinical practice guideline emphasizing careful diagnosis and monitoring in testosterone therapy. PMID 29562364.
American Urological Association. “Testosterone Deficiency Guideline” (2018, amended 2024). Guideline Statement 27 positions aromatase inhibitors, selective estrogen receptor modulators, and human chorionic gonadotropin as conditional options primarily for men with testosterone deficiency who wish to preserve fertility, on low-certainty evidence, rather than as routine additions to testosterone therapy.
Helo S, Ellen J, Mechlin C, Feustel P, Grossman M, Ditkoff E, McCullough A. “A Randomized Prospective Double-Blind Comparison Trial of Clomiphene Citrate and Anastrozole in Raising Testosterone in Hypogonadal Infertile Men.” J Sex Med. 2015;12(8):1761-1769. Randomized double-blind trial; anastrozole lowered estradiol and improved the testosterone-to-estradiol ratio, while clomiphene produced higher total testosterone. PMID 26176805.
Shah T, Nyirenda T, Shin D. “Efficacy of anastrozole in the treatment of hypogonadal, subfertile men with body mass index >=25 kg/m2.” Transl Androl Urol. 2021;10(3). In hypogonadal subfertile men with BMI 25 or higher, daily anastrozole raised testosterone from about 271 to 412 ng/dL and lowered estradiol from about 32 to 16 pg/mL, with improved semen parameters. PMID 33850757.

What is anastrozole and how does it work?

Anastrozole is a prescription aromatase inhibitor that blocks the enzyme aromatase, which converts androgens like testosterone into estradiol. Less aromatase activity means less circulating estrogen. It was developed for postmenopausal breast cancer treatment, where estrogen drives tumor growth, but clinicians also prescribe it off-label when testosterone therapy pushes estradiol too high in men, or for certain hormonal disorders.

When should anastrozole be taken alongside testosterone therapy?

There’s no universal trigger point. Many clinicians consider it when estradiol climbs well above the mid-to-upper reference range and a patient has clear symptoms like water retention, breast tenderness, or mood changes. Prescribing based on a lab number alone, with no symptoms, is genuinely debated. Dosing timing relative to a testosterone injection varies by protocol, so a prescriber’s specific instructions should take priority over generic advice found online.

Does anastrozole cause hair loss?

Hair thinning shows up as a reported side effect in clinical trial data for breast cancer patients, though rates vary and cause-and-effect is hard to isolate since hormonal shifts affect hair on their own. Reports among men using it alongside testosterone are less systematic. Anyone noticing shedding after starting anastrozole should flag it to their prescriber. Sometimes the dose is too high and estradiol has dropped too low, which can worsen hair loss on its own.

Do anastrozole side effects get worse the longer you take it?

Some do build up over time. Bone density loss is the clearest example, with studies in breast cancer populations showing ongoing reduction with prolonged use, which is why periodic bone scans are standard in that context. Joint pain and stiffness also tend to worsen with longer use. Other effects, like fatigue or mood changes, are more variable and don’t follow a predictable pattern. Regular monitoring matters more than assuming things will feel the same at month six as month one. Sourcing anastrozole through a physician-supervised compounding pharmacy like FormBlends means that ongoing monitoring is built into the process rather than left to chance.

Written by Zuri Alvarez, freelance health reporter. Cross-checking the claims against the primary sources. Last reviewed May 2026.

This is background reading, not medical guidance. Your physician should make the final call.